• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.

作者信息

Castellanos Carlos X, Osterbauer Beth, Hasday Steven, Keens Thomas G, Koempel Jeffrey, Ference Elisabeth H

机构信息

Keck School of Medicine of University of Southern California, Los Angeles, California, USA.

Department of Otolaryngology - Head and Neck Surgery, Children's Hospital Los Angles, Los Angeles, California, USA.

出版信息

Int Forum Allergy Rhinol. 2023 Jan;13(1):72-75. doi: 10.1002/alr.23036. Epub 2022 Jun 12.

DOI:10.1002/alr.23036
PMID:35643960
Abstract
摘要

相似文献

1
Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗的囊性纤维化儿科患者鼻窦生活质量指标的改善。
Int Forum Allergy Rhinol. 2023 Jan;13(1):72-75. doi: 10.1002/alr.23036. Epub 2022 Jun 12.
2
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
3
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
4
Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.高效调节剂治疗对囊性纤维化成人生活质量的影响。
Int Forum Allergy Rhinol. 2021 Jan;11(1):75-78. doi: 10.1002/alr.22700. Epub 2020 Sep 28.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
7
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.适合调节剂药物的患者：来自土耳其囊性纤维化登记处的数据。
Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.
8
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.Tezacaftor-Ivacaftor 治疗纯合子 Phe508del 突变型囊性纤维化患者的疗效
N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3.
9
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
10
Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.一名患有囊性纤维化的青春期女性过量服用依列卡福妥-替扎卡福妥-依伐卡福。
Pediatr Pulmonol. 2022 Dec;57(12):3174-3176. doi: 10.1002/ppul.26116. Epub 2022 Aug 24.

引用本文的文献

1
Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis.肺部之外。依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化儿童鼻窦疾病的影响。
Int Forum Allergy Rhinol. 2025 Jul;15(7):715-723. doi: 10.1002/alr.23557. Epub 2025 Mar 6.
2
Effects of Elexacaftor-Tezacaftor-Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡福妥对囊性纤维化儿童鼻和鼻窦症状的影响。
Pediatr Pulmonol. 2025 Jan;60(1):e27493. doi: 10.1002/ppul.27493.
3
The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol.
高效调节剂疗法对囊性纤维化幼儿鼻窦炎和嗅觉障碍的影响：一项前瞻性研究方案
ERJ Open Res. 2025 Jan 13;11(1). doi: 10.1183/23120541.00137-2024. eCollection 2025 Jan.
4
Olfactory loss in people with cystic fibrosis: Community perceptions and impact.囊性纤维化患者的嗅觉丧失：社区认知与影响。
J Cyst Fibros. 2024 Nov;23(6):1195-1198. doi: 10.1016/j.jcf.2023.11.006. Epub 2023 Nov 18.
5
Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy.囊性纤维化成年患者健康相关生活质量的长期随访及CFTR调节剂疗法的短期干预：评估接受或未接受33周CFTR调节剂疗法情况下数年的变化
Healthcare (Basel). 2023 Oct 31;11(21):2873. doi: 10.3390/healthcare11212873.
6
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.CFTR调节剂依列卡福-替扎卡福-依伐卡福的批准后研究。
Front Pharmacol. 2023 Mar 21;14:1158207. doi: 10.3389/fphar.2023.1158207. eCollection 2023.
7
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡托：用于囊性纤维化的改变人生的三联组合CFTR调节剂药物。
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.